NAMI-A and KP1019/1339, two iconic ruthenium anticancer drug candidates face-to-face: A case story in medicinal inorganic chemistry

E Alessio, L Messori - Molecules, 2019 - mdpi.com
NAMI-A ((ImH)[trans-RuCl4 (dmso-S)(Im)], Im= imidazole) and KP1019/1339
(KP1019=(IndH)[trans-RuCl4 (Ind) 2], Ind= indazole; KP1339= Na [trans-RuCl4 (Ind) 2]) are …

Metallodrugs in medicinal inorganic chemistry

KD Mjos, C Orvig - Chemical reviews, 2014 - ACS Publications
Metal ions play important roles in biological processes, 1 and the field of knowledge
concerned with the application of inorganic chemistry to therapy or diagnosis of disease is …

Thirty years of the drug candidate NAMI‐A and the myths in the field of ruthenium anticancer compounds: a personal perspective

E Alessio - European Journal of Inorganic Chemistry, 2017 - Wiley Online Library
As anticipated in the title, this contribution is basically divided into two, strictly connected,
parts. The first is a personal overview of the ruthenium drug candidate NAMI‐A, almost 30 …

Mixed quantum mechanical/molecular mechanical molecular dynamics simulations of biological systems in ground and electronically excited states

E Brunk, U Rothlisberger - Chemical reviews, 2015 - ACS Publications
The quantum nature of electrons and nuclei is manifested in countless biological events
including the rearrangements of electrons in biochemical reactions, electron and proton …

Metal-based anticancer chemotherapeutic agents

N Muhammad, Z Guo - Current opinion in chemical biology, 2014 - Elsevier
Highlights•Rational design of Pt IV prodrugs to reduce toxicity and resistance of clinical Pt II
drugs.•Conjugation of targeting or imaging agents to Pt IV centers.•Multinuclear Pt II …

Piano stool Ru (II)-arene complexes having three monodentate legs: A comprehensive review on their development as anticancer therapeutics over the past decade

S Swaminathan, J Haribabu, N Balakrishnan… - Coordination chemistry …, 2022 - Elsevier
The popularity of RAPTA-C in in vivo studies has steered the way for complexes of the type
[Ru (η 6-arene)(X)(Y)(Z)] n+ (where X, Y and Z are monodentate ligands) to be developed …

Challenges and opportunities in the development of organometallic anticancer drugs

CG Hartinger, N Metzler-Nolte, PJ Dyson - Organometallics, 2012 - ACS Publications
This review provides an introduction into the fascinating area of organometallic anticancer
compounds. Although the subject dates back many years, it has witnessed considerable …

Bioactive luminescent transition‐metal complexes for biomedical applications

DL Ma, HZ He, KH Leung, DSH Chan… - Angewandte Chemie …, 2013 - Wiley Online Library
The serendipitous discovery of the anticancer drug cisplatin cemented medicinal inorganic
chemistry as an independent discipline in the 1960s. Luminescent metal complexes have …

An overview of advancement of organoruthenium (II) complexes as prospective anticancer agents

M Bashir, IA Mantoo, F Arjmand, S Tabassum… - Coordination Chemistry …, 2023 - Elsevier
The successful clinical translation of platinum drugs for cancer treatment has witnessed an
upsurge in the development of metal compounds as therapeutics and diagnostics drugs …

Anticancer cyclometalated complexes of platinum group metals and gold

N Cutillas, GS Yellol, C de Haro, C Vicente… - Coordination chemistry …, 2013 - Elsevier
The clinical success of cisplatin and its derivatives has had an enormous impact on the
discovery of novel metal-based drugs. Extensive studies have focused on the interaction of …